Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZAJGM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
bL-M09D1
|
|||||
| Synonyms |
BL-M09D1
Click to Show/Hide
|
|||||
| Organization |
Sichuan Biokin Pharmaceutical (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-CEA mAb
|
Antibody Info | ||||
| Antigen Name |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5); Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6)
|
Antigen Info | ||||
| Payload Name |
Ed-04
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Gly-Mal-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
brengitecan
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Lung cancer |
1 Trials
|
|||||||||
| Unspecific solid tumor |
2 Trials
|